drugset / Trial / NCT05265052
3D1002 in Combination With Oxycodone Hydrochloride Sustained-release Tablets in Patients With Moderate to Severe Cancer Pain
RandomizedParallel-groupOpen-labelTreatment
Summary
This study aims to evaluate the safety and efficacy of 3D1002 alone or in combination with oxycodone hydrochloride sustained-release tablets (OxyContin) for the management of moderate or severe cancer pain.
Timeline
- Start
- 2026-12
- Primary completion
- 2026-12
- Completion
- 2026-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | 3D1002 | Unknown | 50 mg | Oral |
| Subject | 3D1002 | Unknown | 100 mg | Oral |
| Subject | 3D1002 | Unknown | 150 mg | Oral |
| Subject | Oxycodone | Other / unclassified | 10 mg | — |
Indications
No indication recorded.